This analysis further supports the notion that the TYRP1 transcript level is stable also in clinical samples of relapsed melanomas that are resistant to BRAFV600 and BRAFV600 + MEK1/2 inhibitors. This evidence concerns the gene MAP2K1 and melanoma.